NKTR Stock Plunges on Rezpegaldesleukin Data; William Blair Maintains Durability View
Nektar Therapeutics (NKTR) shares dropped 21% on Thursday after the company presented new response rate data for its experimental skin drug, rezpegaldesleukin. While the drug reportedly maintained efficacy after treatment stopped, the new response rates were modest and derived from small patient groups, putting the sto